Business · 23/10/20261 min read
Paradigm Therapeutics, Inc. announces that the first patient to be admitted to the Phase 3 study on SD-101 (ZorblesiaTM) for epidermolysis bullosa was a new patient in the family of EDF-D2 and EDF.
Summary
SD-101 (ZorblesiaTM) is the first topical therapy to be developed for the treatment of wounds and lesions on the entire skin surface in patients with the three main subtypes of epidermolysis bullosa...
Original source language: PR Newswire — Global News ReleasesOpen original release →